4-Piperidone Derivatives Reversing Multidrug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs often face multidrug resistance (MDR) issues, where cancer cells become resistant, reducing their effectiveness, and existing compounds may exhibit toxicity and genotoxic properties, limiting their therapeutic potential.
Innovation Solution
Development of novel 4-piperidone derivatives with specific structural modifications that are structurally divergent from existing anticancer drugs, capable of reversing MDR and demonstrating enhanced cytotoxicity against cancer cells while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer drugs are used, then cancer treatment is effective, but multidrug resistance develops reducing effectiveness
Solution Approach 1:
The patent modifies molecular parameters of anticancer agents by introducing specific structural modifications to the core scaffold compounds. These changes include adding functional groups, modifying side chains, and adjusting molecular weight to create derivatives that overcome multidrug resistance mechanisms while maintaining cytotoxic activity against resistant cancer cell lines
Solution Approach 2:
The invention creates composite molecular structures by combining existing anticancer active moieties with new structural elements. The compounds integrate multiple functional characteristics into single molecular entities, achieving both cytotoxicity and MDR reversal capabilities that neither component alone could provide
2Productivity
If existing antineoplastic agents are used, then cancer cells are killed, but genotoxic properties cause harmful effects
Solution Approach 1:
The patent converts the harmful genotoxic properties of conventional alkylating agents into beneficial selective cytotoxicity. By modifying the molecular structure to reduce non-specific DNA reactivity while enhancing cancer cell-specific targets, the compounds achieve effective cancer cell killing without the harmful genotoxic side effects
Solution Approach 2:
The invention introduces local quality differentiation by adding functional groups and structural features that create selective interaction with cancer cell-specific targets. The modified molecules exhibit different binding affinities and reaction characteristics that are favorable toward cancer cells while sparing normal cells, thereby reducing genotoxicity
3Ease of manufacture
If structurally similar compounds are used, then synthesis is easier, but cross resistance to contemporary medications occurs
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core scaffold providing cytotoxic activity and detachable side chains or functional groups that can be independently modified. This modular approach allows easy synthesis of parent compounds while enabling systematic generation of diverse derivatives to overcome cross resistance
Solution Approach 2:
The invention transitions from two-dimensional structural similarity to three-dimensional structural diversity by introducing chiral centers, stereoisomers, and conformational variations. These dimensional changes create molecules that maintain synthetic accessibility from common precursors while exhibiting distinct biological activities that bypass cross resistance mechanisms
Data Source
AI summary
The present invention relates to 4-piperidone derivatives represented by the following formula (I) and the acid addition salts thereof.The method of preparation and antineoplastic activity of the said compounds are disclosed. A number of the compounds possess submicromolar IC50 and CC50 values and have a selective toxicity for colon cancers and leukemic cells. In addition, many of the compounds are able to reverse multidrug resistance.